A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting
- Conditions
- Atopic Dermatitis
- Registration Number
- NCT05139836
- Lead Sponsor
- AbbVie
- Brief Summary
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study will assess the real-world effectiveness of upadacitinib on early and sustained response along adolescent and adult participants with AD. This study also aims to understand upadacitinib utilization patterns in real-world clinical practice.
Upadacitinib (RINVOQ) is approved in the EU for the treatment of moderate to severe AD in adults and adolescents 12 years and older who are candidates for systemic therapy. Approximately 772 adolescent and adult participants with AD will be enrolled at up to 200 sites in Germany.
Participants will receive oral upadacitinib tablets as prescribed by the physician prior to enrolling in this study in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population, and indication. The overall duration of the study is approximately 2 years.
Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 772
- Body weight >=30 kg at baseline for participants between >=12 and <18 years of age.
- Physician confirmed diagnosis of moderate to severe atopic dermatitis at the time of enrollment.
- Upadacitinib initiated as per the local label. The decision to prescribe upadacitinib must have been made prior to and independently of study participation.
- Medical and medication history available at least for the last 6 months.
- Current participation in interventional research (note: this does not include non-interventional, post-marketing observational studies, or registry participation).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving Disease Control Defined by Atopic Dermatitis Control Tool (ADCT) Total Score <7 Points Month 3 The ADCT is a validated patient self-administered instrument designed to assess atopic dermatitis (AD) control status in adult and adolescent patients (12 years and older). A higher score indicates lower AD control. A score of \>=7 indicates that the patient is not in control.
Percentage of Participants Achieving Disease Control Defined by ADCT Total Score <7 Points Among Participants Who Achieved Disease Control at Month 3 Month 24 The ADCT is a validated patient self-administered instrument designed to assess atopic dermatitis (AD) control status in adult and adolescent patients (12 years and older). A higher score indicates lower AD control. A score of \>=7 indicates that the patient is not in control.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Achieving Disease Control as Defined by ADCT Total Score <7 Points at Month 3 and Maintaining Disease Control Up to 21 Months (Excluding Month 3 - Primary Endpoint) The ADCT is a validated patient self-administered instrument designed to assess atopic dermatitis (AD) control status in adult and adolescent patients (12 years and older). A higher score indicates lower AD control. A score of \>=7 indicates that the patient is not in control.
Time to Achieve ADCT Total Score Reduction >=5 Points from Baseline Up to 24 Months The ADCT is a validated patient self-administered instrument designed to assess atopic dermatitis (AD) control status in adult and adolescent patients (12 years and older). A higher score indicates lower AD control. A score of \>=7 indicates that the patient is not in control.
Percentage of Participants Achieving EASI 90 Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving Disease Control as Defined by ADCT Item 4 (Sleep Problems) <1 Point and All Other Items <2 Points Up to 24 Months The ADCT is a validated patient self-administered instrument designed to assess atopic dermatitis (AD) control status in adult and adolescent patients (12 years and older). A higher score indicates lower AD control. A score of \>=7 indicates that the patient is not in control.
Absolute Score for ADCT Total Score Up to 24 Months The ADCT is a validated patient self-administered instrument designed to assess atopic dermatitis (AD) control status in adult and adolescent patients (12 years and older). A higher score indicates lower AD control. A score of \>=7 indicates that the patient is not in control.
Time to Achieve Disease Control as Defined by ADCT Total Score <7 Points Up to 24 Months The ADCT is a validated patient self-administered instrument designed to assess atopic dermatitis (AD) control status in adult and adolescent patients (12 years and older). A higher score indicates lower AD control. A score of \>=7 indicates that the patient is not in control.
Percentage of Participants with An ADCT Total Score Reduction >=5 from Baseline Up to 24 Months The ADCT is a validated patient self-administered instrument designed to assess atopic dermatitis (AD) control status in adult and adolescent patients (12 years and older). A higher score indicates lower AD control. A score of \>=7 indicates that the patient is not in control.
Absolute Change from Baseline for ADCT Total Score Up to 24 Months The ADCT is a validated patient self-administered instrument designed to assess atopic dermatitis (AD) control status in adult and adolescent patients (12 years and older). A higher score indicates lower AD control. A score of \>=7 indicates that the patient is not in control.
Percent Change from Baseline for ADCT Total Score Up to 24 Months The ADCT is a validated patient self-administered instrument designed to assess atopic dermatitis (AD) control status in adult and adolescent patients (12 years and older). A higher score indicates lower AD control. A score of \>=7 indicates that the patient is not in control.
Percentage of Participants Achieving Absolute EASI <=7 Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percent Change from Baseline for Flare Frequency Up to 24 Months Flare frequency is assessed by acquiring information about the number of flares in the last six months before baseline. During the study the patient is asked about number of flares since the last visit. Additionally, the presence of a current flare is assessed at each visit.
Percentage of Participants Achieving Disease Control Defined by ADCT Total Score <7 Points Up to 24 Months The ADCT is a validated patient self-administered instrument designed to assess atopic dermatitis (AD) control status in adult and adolescent patients (12 years and older). A higher score indicates lower AD control. A score of \>=7 indicates that the patient is not in control.
Percentage of Participants Achieving EASI 75 Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Absolute Change from Baseline for EASI Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percent Change from Baseline for EASI Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Time to Achieve Absolute EASI <=7 Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving EASI 90 in the Head and/or Neck Body Region Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 50 Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Time to Achieve EASI 90 Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving EASI 100 in the Head and/or Neck Body Region Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) <=1 Up to 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Percentage of Participants Achieving a WP-NRS Reduction >=4 from Baseline Up to 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Percentage of Participants Achieving EASI 100 Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Time to Achieve EASI 75 Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Time to Achieve EASI 100 Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving EASI 50 in the Head and/or Neck Body Region Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving EASI 75 in the Head and/or Neck Body Region Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving WP-NRS <=3 Up to 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Absolute Score for EASI Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Time to Achieve EASI 50 Up to 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Time to Achieve WP-NRS <=1 Up to 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Percent Change from Baseline for DLQI/cDLQI Up to 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL. For patients from age 12-15 the cDLQI is used.
Percent Change from Baseline for Stigmatization (6-Item Stigmatization Scale) Up to 24 Months The scale consists of 6 items that address the feeling of stigmatization because of this condition. The participants respond to each item by 0 (not at all), 1 (sometimes), 2 (very often), or 3 (always). The sum of the responses to the 6 items generates a score ranging from 0 to 18 with higher scores corresponding to a higher feeling of stigmatization.
Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) <=1 Up to 24 Months vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis (no erythema, no induration/papulation, no lichenification, no oozing/crusting). Post-inflammatory hyperpigmentation and/or hypopigmentation may be present.) to 4 - Severe (marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification.
Percentage of Participants Achieving DLQI/cDLQI Reduction >=4 from Baseline Up to 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL. For patients from age 12-15 the cDLQI is used.
Absolute Change from Baseline for DLQI/cDLQI Up to 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL. For patients from age 12-15 the cDLQI is used.
Percent Change from Baseline for HADS-A Up to 24 Months The HADS is a 14-item self-report scale, It contains two 7-item scales: one for anxiety (HADS-A) and one for depression (HADS-D). Each HADS item is rated on a 4-point Likert-type scale with total scores on each subscale ranging from 0 to 21, and with higher scores corresponding to greater respective symptom severity.
Percent Change from Baseline for HADS-D Up to 24 Months The HADS is a 14-item self-report scale, It contains two 7-item scales: one for anxiety (HADS-A) and one for depression (HADS-D). Each HADS item is rated on a 4-point Likert-type scale with total scores on each subscale ranging from 0 to 21, and with higher scores corresponding to greater respective symptom severity.
Absolute Change from Baseline for Stigmatization (6-Item Stigmatization Scale) Up to 24 Months The scale consists of 6 items that address the feeling of stigmatization because of this condition. The participants respond to each item by 0 (not at all), 1 (sometimes), 2 (very often), or 3 (always). The sum of the responses to the 6 items generates a score ranging from 0 to 18 with higher scores corresponding to a higher feeling of stigmatization.
Absolute Score for WP-NRS Up to 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Percent Change from Baseline for WP-NRS Up to 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Absolute Change from Baseline for SCORAD Sleep VAS Up to 24 Months The sleep VAS is one component from the SCORAD test that measures the intensity of sleeplessness during a three day or night recall period. The test uses a VAS scale of 0 to 10 with 0 being "no sleeplessness" and 10 being "worst imaginable sleeplessness".
Absolute Score for Score Atopic Dermatitis (SCORAD) Sleep Visual Analog Scale (VAS) Up to 24 Months The sleep VAS is one component from the SCORAD test that measures the intensity of sleeplessness during a three day or night recall period. The test uses a VAS scale of 0 to 10 with 0 being "no sleeplessness" and 10 being "worst imaginable sleeplessness".
Percent Change from Baseline for SCORAD Sleep VAS Up to 24 Months The sleep VAS is one component from the SCORAD test that measures the intensity of sleeplessness during a three day or night recall period. The test uses a VAS scale of 0 to 10 with 0 being "no sleeplessness" and 10 being "worst imaginable sleeplessness".
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI)/Children's Dermatology Life Quality Index (cDLQI) <=1 Up to 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL. For patients from age 12-15 the cDLQI is used.
Absolute Score for DLQI/cDLQI Up to 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL. For patients from age 12-15 the cDLQI is used.
Absolute Score for Hospital Anxiety and Depression Scale for Anxiety (HADS-A) Up to 24 Months The HADS is a 14-item self-report scale, It contains two 7-item scales: one for anxiety (HADS-A) and one for depression (HADS-D). Each HADS item is rated on a 4-point Likert-type scale with total scores on each subscale ranging from 0 to 21, and with higher scores corresponding to greater respective symptom severity.
Absolute Change from Baseline for HADS-A Up to 24 Months The HADS is a 14-item self-report scale, It contains two 7-item scales: one for anxiety (HADS-A) and one for depression (HADS-D). Each HADS item is rated on a 4-point Likert-type scale with total scores on each subscale ranging from 0 to 21, and with higher scores corresponding to greater respective symptom severity.
Absolute Score for Hospital Anxiety and Depression Scale for Depression (HADS-D) Up to 24 Months The HADS is a 14-item self-report scale, It contains two 7-item scales: one for anxiety (HADS-A) and one for depression (HADS-D). Each HADS item is rated on a 4-point Likert-type scale with total scores on each subscale ranging from 0 to 21, and with higher scores corresponding to greater respective symptom severity.
Absolute Change from Baseline for HADS-D Up to 24 Months The HADS is a 14-item self-report scale, It contains two 7-item scales: one for anxiety (HADS-A) and one for depression (HADS-D). Each HADS item is rated on a 4-point Likert-type scale with total scores on each subscale ranging from 0 to 21, and with higher scores corresponding to greater respective symptom severity.
Absolute Change from Baseline for WP-NRS Up to 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Percentage of Participants Achieving DLQI/cDLQI <=5 Up to 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL. For patients from age 12-15 the cDLQI is used.
Percent Change from Baseline for Skin Pain on the ADerm-SS Up to 24 Months Skin pain and skin cracking are assessed by a one item test from the ADERM-SS to measure the intensity of skin pain/skin cracking during the past 24 hours. The test uses a scale of 0 to 10, with 0 being "no skin pain"/"no skin cracking" and 10 bring the "worst imaginable skin pain"/"worst imaginable skin cracking".
Percent Change from Baseline for Skin Cracking on the ADerm-SS Up to 24 Months Skin pain and skin cracking are assessed by a one item test from the ADERM-SS to measure the intensity of skin pain/skin cracking during the past 24 hours. The test uses a scale of 0 to 10, with 0 being "no skin pain"/"no skin cracking" and 10 bring the "worst imaginable skin pain"/"worst imaginable skin cracking".
Absolute Score for vIGA-AD of Facial Eczema Up to 24 Months The vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. It consists of a 5-point scale used by the investigator to measure the severity of disease ranging from 0 - Clear to 4 - Severe.
Absolute Change from Baseline for Pruritis (5-D Pruritis Scale) Up to 24 Months The 5-D pruritis scale is a brief but multidimensional questionnaire for the quantification of pruritis that is sensitive to change over time. The five dimensions are degree, duration, direction, disability and distribution. The duration, degree and direction domains each include one item, while the disability domain has four items. All items on the first four domains are measured on a five-point Likert scales. The scores of each of the five domains are achieved separately and then summed together to obtain a total 5-D score. 5-D scores can potentially range between 5 (no pruritis) and 25 (most severe pruritis).
Absolute Change from Baseline for Flare Frequency Up to 24 Months Flare frequency is assessed by acquiring information about the number of flares in the last six months before baseline. During the study the patient is asked about number of flares since the last visit. Additionally, the presence of a current flare is assessed at each visit.
Time to Achieve DLQI/cDLQI <=1 Up to 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL. For patients from age 12-15 the cDLQI is used.
Absolute Score for Stigmatization (6-Item Stigmatization Scale) Up to 24 Months The scale consists of 6 items that address the feeling of stigmatization because of this condition. The participants respond to each item by 0 (not at all), 1 (sometimes), 2 (very often), or 3 (always). The sum of the responses to the 6 items generates a score ranging from 0 to 18 with higher scores corresponding to a higher feeling of stigmatization.
Absolute Score for Asthma Control Test (ACT) in Participants Having a Confirmed Diagnosis of Asthma at Baseline Up to 24 Months The ACT consists of 5 simple questions regarding the patients' asthma symptom burden. For each question there is a range from 1 to 5. A lower score indicates lower asthma control.
Absolute Score for Patient Self-Reported Global Assessment of Disease Severity (PtGA) Up to 24 Months Patients assess the overall severity of their disease by a five-point assessment scale (clear, mild, moderate, severe, or very severe, \[0-4\]), with higher scores corresponding to greater severity.
Absolute Change from Baseline in ACT in Participants Having a Confirmed Diagnosis of Asthma at Baseline Up to 24 Months The ACT consists of 5 simple questions regarding the patients' asthma symptom burden. For each question there is a range from 1 to 5. A lower score indicates lower asthma control.
Percent Change from Baseline in ACT in Participants Having a Confirmed Diagnosis of Asthma at Baseline Up to 24 Months The ACT consists of 5 simple questions regarding the patients' asthma symptom burden. For each question there is a range from 1 to 5. A lower score indicates lower asthma control.
Percentage of Participants with Modification of Upadacitinib Therapy, Timing of Modifications, and Reasons for Modifications 24 Months This includes change in upadacitinib dose with rationale, e.g., dose change, temporary or permanent discontinuation.
Absolute Change from Baseline for Skin Pain on the ADerm-SS Up to 24 Months Skin pain and skin cracking are assessed by a one item test from the ADERM-SS to measure the intensity of skin pain/skin cracking during the past 24 hours. The test uses a scale of 0 to 10, with 0 being "no skin pain"/"no skin cracking" and 10 bring the "worst imaginable skin pain"/"worst imaginable skin cracking".
Absolute Score for Skin Cracking on the ADerm-SS Up to 24 Months Skin pain and skin cracking are assessed by a one item test from the ADERM-SS to measure the intensity of skin pain/skin cracking during the past 24 hours. The test uses a scale of 0 to 10, with 0 being "no skin pain"/"no skin cracking" and 10 bring the "worst imaginable skin pain"/"worst imaginable skin cracking".
Absolute Change from Baseline for Skin Cracking on the ADerm-SS Up to 24 Months Skin pain and skin cracking are assessed by a one item test from the ADERM-SS to measure the intensity of skin pain/skin cracking during the past 24 hours. The test uses a scale of 0 to 10, with 0 being "no skin pain"/"no skin cracking" and 10 bring the "worst imaginable skin pain"/"worst imaginable skin cracking".
Absolute Score for Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) of Hand Eczema Up to 24 Months The vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. It consists of a 5-point scale used by the investigator to measure the severity of disease ranging from 0 - Clear to 4 - Severe.
Absolute Change from Baseline for vIGA-AD of Hand Eczema Up to 24 Months The vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. It consists of a 5-point scale used by the investigator to measure the severity of disease ranging from 0 - Clear to 4 - Severe.
Absolute Change from Baseline for vIGA-AD of Facial Eczema Up to 24 Months The vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. It consists of a 5-point scale used by the investigator to measure the severity of disease ranging from 0 - Clear to 4 - Severe.
Percent Change from Baseline for vIGA-AD of Facial Eczema Up to 24 Months The vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. It consists of a 5-point scale used by the investigator to measure the severity of disease ranging from 0 - Clear to 4 - Severe.
Absolute Score for Pruritis (5-D Pruritis Scale) Up to 24 Months The 5-D pruritis scale is a brief but multidimensional questionnaire for the quantification of pruritis that is sensitive to change over time. The five dimensions are degree, duration, direction, disability and distribution. The duration, degree and direction domains each include one item, while the disability domain has four items. All items on the first four domains are measured on a five-point Likert scales. The scores of each of the five domains are achieved separately and then summed together to obtain a total 5-D score. 5-D scores can potentially range between 5 (no pruritis) and 25 (most severe pruritis).
Percent Change from Baseline for Pruritis (5-D Pruritis Scale) Up to 24 Months The 5-D pruritis scale is a brief but multidimensional questionnaire for the quantification of pruritis that is sensitive to change over time. The five dimensions are degree, duration, direction, disability and distribution. The duration, degree and direction domains each include one item, while the disability domain has four items. All items on the first four domains are measured on a five-point Likert scales. The scores of each of the five domains are achieved separately and then summed together to obtain a total 5-D score. 5-D scores can potentially range between 5 (no pruritis) and 25 (most severe pruritis).
Absolute Score for Flare Duration Up to 24 Months Flare frequency is assessed by acquiring information about the number of flares in the last six months before baseline. During the study the patient is asked about number of flares since the last visit. The mean duration of the flares is also documented. Additionally, the presence of a current flare is assessed at each visit.
Percentage of Participants Achieving Absolute Score >=20 for ACT in Participants Having a Confirmed Diagnosis of Asthma at Baseline Up to 24 Months The ACT consists of 5 simple questions regarding the patients' asthma symptom burden. For each question there is a range from 1 to 5. A lower score indicates lower asthma control.
Percentage of Participants with Modification of Concomitant AD Therapy, Timing of Modifications, and Reasons for Modifications 24 Months This includes change in concomitant AD therapy with rationale, e.g., adding or removing or changing dose of topical corticosteroids/topical calcineurin inhibitors.
Absolute Score for Flare Frequency Up to 24 Months Flare frequency is assessed by acquiring information about the number of flares in the last six months before baseline. During the study the patient is asked about number of flares since the last visit. Additionally, the presence of a current flare is assessed at each visit.
Percent Change from Baseline for PtGA Up to 24 Months Patients assess the overall severity of their disease by a five-point assessment scale (clear, mild, moderate, severe, or very severe, \[0-4\]), with higher scores corresponding to greater severity.
Percentage of Participants Achieving PtGA Reduction >=1 from Baseline Up to 24 Months Patients assess the overall severity of their disease by a five-point assessment scale (clear, mild, moderate, severe, or very severe, \[0-4\]), with higher scores corresponding to greater severity.
Incidence and Type of Adverse Events Up to 24 Months An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug but within 30 days after the last dose of study drug.
Percentage of Participants Starting on Upadacitinib 15 mg or 30 mg Baseline Percentage of participants initiating upadacitinib at 15 mg or 30 mg with rationale.
Absolute Score for Skin Pain on the Atopic Dermatitis Symptom Scale (ADerm-SS) Up to 24 Months Skin pain and skin cracking are assessed by a one item test from the ADERM-SS to measure the intensity of skin pain/skin cracking during the past 24 hours. The test uses a scale of 0 to 10, with 0 being "no skin pain"/"no skin cracking" and 10 bring the "worst imaginable skin pain"/"worst imaginable skin cracking".
Percent Change from Baseline for vIGA-AD of Hand Eczema Up to 24 Months The vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. It consists of a 5-point scale used by the investigator to measure the severity of disease ranging from 0 - Clear to 4 - Severe.
Percent Change from Baseline for Flare Duration Up to 24 Months Flare frequency is assessed by acquiring information about the number of flares in the last six months before baseline. During the study the patient is asked about number of flares since the last visit. The mean duration of the flares is also documented. Additionally, the presence of a current flare is assessed at each visit.
Percentage of Participants Achieving PtGA <=2 Up to 24 Months Patients assess the overall severity of their disease by a five-point assessment scale (clear, mild, moderate, severe, or very severe, \[0-4\]), with higher scores corresponding to greater severity.
Absolute Change from Baseline for Flare Duration Up to 24 Months Flare frequency is assessed by acquiring information about the number of flares in the last six months before baseline. During the study the patient is asked about number of flares since the last visit. The mean duration of the flares is also documented. Additionally, the presence of a current flare is assessed at each visit.
Absolute Change from Baseline for PtGA Up to 24 Months Patients assess the overall severity of their disease by a five-point assessment scale (clear, mild, moderate, severe, or very severe, \[0-4\]), with higher scores corresponding to greater severity.
Trial Locations
- Locations (125)
Timmel/Timm/Vorwerk, Bergen /ID# 241661
🇩🇪Bergen, Germany
Hautarztpraxis Dr. med. Christiane Handrick /ID# 262667
🇩🇪Berlin, Germany
Praxis Dermatologie am Savigny /ID# 248846
🇩🇪Berlin, Germany
Dre. Gellrich/Klein/Soost /ID# 250301
🇩🇪Berlin, Germany
Schirmer, Berlin, DE /ID# 241684
🇩🇪Berlin, Germany
Kors, Berlin, DE /ID# 241847
🇩🇪Berlin, Germany
Dues/Manasterski, Berlin, DE /ID# 243885
🇩🇪Berlin, Germany
Hautarztzentrum Tegel /ID# 241826
🇩🇪Berlin, Germany
Haut Pur - Dermatologische Gemeinschaftspraxis /ID# 243943
🇩🇪Berlin, Germany
Hautarztpraxis Dr. Weid /ID# 265213
🇩🇪Bingen am Rhein, Germany
Praxis fuer Innere Medizin/Rheumatologie /ID# 241846
🇩🇪Blaubeuren, Germany
Praxis T. Schadeck /ID# 241768
🇩🇪Bogen, Germany
Barth, Borna, DE /ID# 248871
🇩🇪Borna, Germany
Schwichtenberg, Bremen, DE /ID# 241683
🇩🇪Bremen, Germany
Dr. Hoffmann /ID# 245423
🇩🇪Cologne, Germany
Derma Köln /ID# 241856
🇩🇪Cologne, Germany
Haut- und Allergie-Zentrum Lippstadt /ID# 241929
🇩🇪Lippstadt, Germany
Hagemeier, Loehne, DE /ID# 241886
🇩🇪Loehne, Germany
Magdeburger Company for Medical Studies & Services GmbH /ID# 248849
🇩🇪Magdeburg, Germany
MVZ "Im Altstadtquartier" Magdeburg /ID# 261366
🇩🇪Magdeburg, Germany
Universitaetsklinikum Magdeburg /ID# 249174
🇩🇪Magdeburg, Germany
Hausärzte am Fastnachtsbrunnen /ID# 250304
🇩🇪Mainz, Germany
Dermatologie Quist-BAG Dres. med. Quist PartG /ID# 243325
🇩🇪Mainz, Germany
Praxis A. Viculova /ID# 266133
🇩🇪Miltenberg, Germany
Dermatologie im Tal Praxis Dr.med. Maria Leibl /ID# 266128
🇩🇪Munich, Germany
Hautzentrum am Marienplatz /ID# 248847
🇩🇪Munich, Germany
Quack, Munich, DE /ID# 241536
🇩🇪Munich, Germany
Dr. Gißler-Walter /ID# 248876
🇩🇪Mutterstadt, Germany
ZENTderma /ID# 241539
🇩🇪Mönchengladbach, Germany
Dr. Rezai /ID# 250298
🇩🇪Münster, Germany
Dermatologie im Apfelgarten /ID# 263704
🇩🇪Neu Wulmstorf, Germany
Praxis Dr. Konstantin Ertner /ID# 249153
🇩🇪Nuremberg, Germany
Hockmann, Oelde, DE /ID# 241906
🇩🇪Oelde, Germany
Harzklinikum Dorothea Christiane Erxleben /ID# 251067
🇩🇪Quedlinburg, Germany
Dr. Schaefers /ID# 255492
🇩🇪Reutlingen, Germany
Praxis Dr. Fränken /ID# 241853
🇩🇪Schwelm, Germany
Gemeinschaftspraxis fur Dermatologie /ID# 245831
🇩🇪Stadtroda, Germany
Praxis Dr. Termeer /ID# 241662
🇩🇪Stuttgart, Germany
Jasnoch/Kock/Borrosch, Vechta, /ID# 252081
🇩🇪Vechta, Germany
Barnikol, Waltershausen, DE /ID# 241844
🇩🇪Waltershausen, Germany
Praxis Dehmel / Brand-Opitzer /ID# 243884
🇩🇪Wasserburg A. Inn, Germany
Dr. Barbara Kempkes, Werne /ID# 241910
🇩🇪Werne, Germany
Dr. med. Nicola Möller & Thomas Kurtenbach GbR Dermatologie im Zentrum /ID# 266130
🇩🇪Wiesbaden, Germany
Hautarztpraxis Dr. med. Matthias Hoffmann /ID# 241907
🇩🇪Witten, Germany
Albrecht, Wurzen, DE /ID# 241988
🇩🇪Wurzen, Germany
Durani & Durani, Heidelberg,DE /ID# 249172
🇩🇪Heidelberg, Baden-Wuerttemberg, Germany
Universitaetsklinik Heidelberg /ID# 245834
🇩🇪Heidelberg, Baden-Wuerttemberg, Germany
Hautarztpraxis Langenau /ID# 242279
🇩🇪Langenau, Baden-Wuerttemberg, Germany
Flegl MD Stuttgart Germany /ID# 250302
🇩🇪Stuttgart, Baden-Wuerttemberg, Germany
Mauer, Bad Kreuznach, DE /ID# 241990
🇩🇪Bad Kreuznach, Germany
Kurzen, Freising, DE /ID# 241845
🇩🇪Freising, Bayern, Germany
Beldio Research GmbH /ID# 245830
🇩🇪Memmingen, Bayern, Germany
Dermazent /Id# 268146
🇩🇪Munich, Bayern, Germany
Voelkel, Nuremberg, DE /ID# 252445
🇩🇪Nuremberg, Bayern, Germany
Hautarzte im Novum Medicum Dr. Kreienkamp & Sautter /ID# 276060
🇩🇪Wuerzburg, Bayern, Germany
Praxis Dres. Freitag/Knoell /ID# 242278
🇩🇪Falkensee, Brandenburg, Germany
Dermatologie Kleinmachnow /ID# 268383
🇩🇪Kleinmachnow, Brandenburg, Germany
Praxis Dr. Behnke /ID# 248870
🇩🇪Panketal, Brandenburg, Germany
Praxis Dr. Asadullah /ID# 243944
🇩🇪Potsdam, Brandenburg, Germany
Hautärzte am Nauener Tor /ID# 261533
🇩🇪Potsdam, Brandenburg, Germany
Hautarztpraxis Dr. Alexander Magerl /ID# 270749
🇩🇪Bensheim, Hessen, Germany
Universitaetsklinikum Frankfurt /ID# 241766
🇩🇪Frankfurt am Main, Hessen, Germany
MediCorium Zentrum fuer Dermatologie und Aesthetik /ID# 243328
🇩🇪Oberursel, Hessen, Germany
MediCorium Zentrum fuer Dermatologie und Aesthetik /ID# 249180
🇩🇪Oberursel, Hessen, Germany
Hautcentrum Wiesbaden /ID# 274848
🇩🇪Wiesbaden, Hessen, Germany
Herrmann, Greifswald, DE /ID# 241889
🇩🇪Greifswald, Mecklenburg-Vorpommern, Germany
Studienzentrum an der Hase GbR Dr. Weyergraf/Dr. Frick/Thomas Heiber /ID# 241658
🇩🇪Bramsche, Niedersachsen, Germany
Praxis Dres. Kaspari /Schenck /ID# 241688
🇩🇪Hannover, Niedersachsen, Germany
Hoeller-Obrigkeit, Aachen, DE /ID# 245430
🇩🇪Aachen, Nordrhein-Westfalen, Germany
Klinikum Rosenhoehe /ID# 241601
🇩🇪Bielefeld, Nordrhein-Westfalen, Germany
Katholisches Klinikum Bochum gGmbH /ID# 270537
🇩🇪Bochum, Nordrhein-Westfalen, Germany
Kramer/Mortazawi, Remscheid /ID# 241824
🇩🇪Remscheid, Nordrhein-Westfalen, Germany
Karl, Soest, DE /ID# 241909
🇩🇪Soest, Nordrhein-Westfalen, Germany
Bell, Andernach, DE /ID# 249154
🇩🇪Andernach, Rheinland-Pfalz, Germany
Grossmann, Koblenz, DE /ID# 242992
🇩🇪Koblenz, Rheinland-Pfalz, Germany
Hautarztpraxis Dr. Kirschner /ID# 266738
🇩🇪Mainz, Rheinland-Pfalz, Germany
CMS3 Company for Medical Study /ID# 241659
🇩🇪Selters, Rheinland-Pfalz, Germany
Dermatologisches Studienzentrum am Haut- und Laserzentrum /ID# 243882
🇩🇪Simmern, Rheinland-Pfalz, Germany
HMS GmbH Zimmer /ID# 241657
🇩🇪Merzig, Saarland, Germany
Praxis Dr. Raschke /ID# 251398
🇩🇪Magdeburg, Sachsen-Anhalt, Germany
Praxis P. Hausler-Mehlhorn /ID# 241527
🇩🇪Chemnitz, Sachsen, Germany
Neubauer, Leipzig, DE /ID# 241823
🇩🇪Leipzig, Sachsen, Germany
Praxis Dr. Mempel /ID# 241827
🇩🇪Elmshorn, Schleswig-Holstein, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 240096
🇩🇪Kiel, Schleswig-Holstein, Germany
Dermatologie Moelln Praxis Dr. Bodo Segert /ID# 242280
🇩🇪Mölln, Schleswig-Holstein, Germany
Praxis Liebetrau /ID# 271896
🇩🇪Friedrichroda, Thueringen, Germany
Petri, Ahaus, DE /ID# 243452
🇩🇪Ahaus, Germany
Dr. Stoeber /ID# 251066
🇩🇪Ahlen, Germany
Praxis Dr. Mihaescu /ID# 241825
🇩🇪Augsburg, Germany
MVZ medicum.mittelhessen /ID# 266126
🇩🇪Bad Camberg, Germany
Praxis Dr. Sbornik /ID# 241818
🇩🇪Deggendorf, Germany
Hautmedizin Delitzsch /ID# 251394
🇩🇪Delitzsch, Germany
Richter-Huhn, Dresden, DE /ID# 241822
🇩🇪Dresden, Germany
Praxis Dr. Korge /ID# 241531
🇩🇪Dueren, Germany
Praxis Dr. Hong-Weldemann /ID# 248844
🇩🇪Freiburg im Breisgau, Germany
Hautarztpraxis Friedberg Dr. med. Wilfried Jungkunz /ID# 248851
🇩🇪Friedberg (Hessen), Germany
Rotterdam, Gelsenkirchen, DE /ID# 241819
🇩🇪Gelsenkirchen, Germany
Gemeinschaftspraxis Rietkoetter und Jablonka /ID# 241821
🇩🇪Gelsenkirchen, Germany
Praxis Dr. Lange /ID# 241829
🇩🇪Gera, Germany
Loth, Gernsbach, DE /ID# 241828
🇩🇪Gernsbach, Germany
Hautarztpraxis Dr. Budihardja /ID# 241851
🇩🇪Gießen, Germany
Brinkmann & Partner, Gladbeck, /ID# 241850
🇩🇪Gladbeck, Germany
Dr. Krueger /ID# 265150
🇩🇪Goslar, Germany
Grossmann, Grossenhain, DE /ID# 250303
🇩🇪Grossenhain, Germany
Praxis Dr. Wegener /ID# 263731
🇩🇪Hamburg, Germany
Cutaneum /ID# 249104
🇩🇪Hamburg, Germany
Dermatologikum Hamburg /ID# 245431
🇩🇪Hamburg, Germany
Hautarztpraxis Luetten/Sack /ID# 241534
🇩🇪Hamburg, Germany
Dr. Wrage-Brors /ID# 262705
🇩🇪Hamburg, Germany
Mensing Derma MVZ GmbH /ID# 272383
🇩🇪Hamburg, Germany
Praxis Dr. Kasche /ID# 249102
🇩🇪Hamburg, Germany
MVZ Prof. Dr. Ockenfels Haut- und Allergie-Praxisklinik GmbH /ID# 245395
🇩🇪Hanau, Germany
Dr. Buerkle /ID# 250299
🇩🇪Haslach im Kinzigtal, Germany
Hautarztpraxis Haßberge /ID# 257648
🇩🇪Haßfurt, Germany
Gemeinschaftspraxis Dres. Anika Hünermund/Mario Pawlak /ID# 241908
🇩🇪Heilbad Heiligenstadt, Germany
Haut- u. Laserzentrum Heilbronn /ID# 250305
🇩🇪Heilbronn, Germany
Hausarztpraxis & Laserzentrum Dr. Zimmermann & Kollegen /ID# 251051
🇩🇪Heusenstamm, Germany
Praxis Dres. Bischoff/Danz /ID# 241852
🇩🇪Ilmenau, Germany
Stockmeier, Ingoldstadt, DE /ID# 248877
🇩🇪Ingolstadt, Germany
Hautarztpraxis Weidgang /ID# 248850
🇩🇪Juelich, Germany
Derma Sana /ID# 241854
🇩🇪Karlsruhe, Germany
Dermatologische Praxis Kempen /ID# 248852
🇩🇪Kempen, Germany
Praxis Dres. Bornemann/Reinerth /ID# 257649
🇩🇪Krefeld, Germany
Dres. Jacobs & Kollegen /ID# 241989
🇩🇪Kulmbach, Germany
Praxis Dres. Wiemers/Wiemers /ID# 241602
🇩🇪Leipzig, Germany